CD274 and hepatocellular carcinoma: Immunotherapy subsequently emerged as first line therapy in advanced-stage HCC following the IMbrave150 trial which showed superior overall and progression free survival with anti-programmed cell death-ligand 1 (PD-L1) atezolizumab in combination with anti-vascular endothelial growth factor (VEGF) bevacizumb compared to sorafenib [152].